Home › IMBRUVICA (ibrutinib) Shows Durable, Long-Term Responses for Patients with CLL
 

Keywords :   


IMBRUVICA (ibrutinib) Shows Durable, Long-Term Responses for Patients with CLL

2014-06-01 03:48:06| Logistics - Topix.net

Pharmacyclics, Inc. announced today that IMBRUVICA will be featured in an oral presentation highlighting long-term responses to treatment, with up to three years of follow up in 132 patients with treatment naive or relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma .

Tags: shows patients responses durable

Category:Transportation and Logistics

Latest from this category

All news
24.11Atlantic Tropical Weather Outlook
24.11Eastern North Pacific Tropical Weather Outlook
24.11Eastern North Pacific Tropical Weather Outlook
24.11Atlantic Tropical Weather Outlook
24.11Atlantic Tropical Weather Outlook
24.11Eastern North Pacific Tropical Weather Outlook
23.11Atlantic Tropical Weather Outlook
23.11Eastern North Pacific Tropical Weather Outlook
Transportation and Logistics »
24.11S
24.11
24.115
24.11SR
24.11 RC24.4.5
24.11115+128717dz
24.11lavaSUKALA 3
24.11508A
More »